Top Industry Leaders in the Europe Gastrointestinal Drugs Market
Latest Europe, the Middle East and Africa Gastrointestinal Drugs Companies Update
October 2023: Self-insured companies and plan sponsors around the country planned to take advantage of Parsley Health's gastrointestinal program, a digital health initiative aimed at reducing expenses in patients with complicated and chronic diseases through the use of root cause medicine. Employers may save money with this innovative benefit, which targets the roughly 50% of women and 37% of men who have at least one gastrointestinal issue. For both sexes combined, the direct cost of treating gastrointestinal conditions is over $135 billion per year, placing it in the top five expense categories for businesses. Autoimmunity, hormone balance, and mental health are all impacted by gastrointestinal disorders. Their most recent poll of working women confirmed that this is a major reason why women miss time in the office. Intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), Crohn's disease (CD), and other gastrointestinal disorders are all covered extensively in the curriculum.
July 2022: The launch of the blockbuster biologic medication Vedolizumab in India was announced by Takeda India, a division of the Japanese pharmaceutical firm Takeda Pharmaceutical Company. The drug is part of the Gastrointestinal (GI) portfolio. Haematology, Genetic Diseases, and Immunology is Takeda's first therapeutic area in India, whereas GI is their second. For the treatment of chronic inflammatory bowel illnesses (IBD), including Ulcerative Colitis (UC) and Crohn's Disease (CD), vedolizumab will be offered in India under the brand name Kynteles. Kynteles has demonstrated positive safety and effectiveness outcomes in the treatment of individuals with moderate to severe inflammatory bowel disease (IBD), according to the business. The business did not reveal the pricing, but they did say it will be priced with the Indian market's affordability and accessibility in mind.List of Europe, the Middle East and Africa Gastrointestinal Drugs Key companies in the market
- AstraZeneca Plc.(UK)
- Johnson & Johnson (US)
- Takeda Pharmaceutical Company Limited (Japan)
- Eisai Co., Ltd. (Japan)
- Valeant Pharmaceuticals Inc. (US)
- Sanofi Ltd. (France)
- Valeant (US)
- Abbott Laboratories(US)
- Allergan Plc (US)
- Bayer AG (Germany)
- Janssen Biotech Inc. (US)
- AbbVie Inc. (US)
- Janssen Biotech (US)
- GlaxoSmithKline Plc. (UK)
- Boehringer Ingelheim GmbH (Germany)